{
  "summary": {
    "root_cause": "Data sparsity - mAbs have 5x fewer training examples per drug",
    "original_predictions": 1042,
    "oncology_mab_filtered": 16,
    "new_predictions": 1026
  },
  "mab_class_performance": {
    "anti_tnf": "100% strong",
    "anti_cd20": "100% strong",
    "checkpoint": "42% strong",
    "anti_her2": "0% strong",
    "anti_egfr": "17% strong"
  },
  "oncology_mabs_filtered": [
    "trastuzumab",
    "pertuzumab",
    "cetuximab",
    "panitumumab",
    "bevacizumab",
    "ramucirumab",
    "necitumumab"
  ],
  "filtered_predictions": [
    {
      "drug": "Trastuzumab",
      "disease": "melanoma",
      "validation_score": 0.154,
      "adjusted_score": 0.154,
      "evidence_level": "weak",
      "trial_count": 7,
      "pub_count": 87,
      "recent_pubs": 22,
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "has_trials": true,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": null,
      "model_score": null
    },
    {
      "drug": "Panitumumab",
      "disease": "gastric adenocarcinoma",
      "validation_score": 0.062,
      "adjusted_score": 0.062,
      "evidence_level": "weak",
      "trial_count": 5,
      "pub_count": 2,
      "recent_pubs": 1,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "has_trials": true,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": null,
      "model_score": null
    },
    {
      "drug": "Trastuzumab",
      "disease": "metastatic melanoma",
      "validation_score": 0.029,
      "adjusted_score": 0.029,
      "evidence_level": "weak",
      "trial_count": 2,
      "pub_count": 6,
      "recent_pubs": 0,
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "has_trials": true,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.7750150102353942,
      "model_score": 1.0920306834587326
    },
    {
      "drug": "Bevacizumab",
      "disease": "descending colon cancer",
      "validation_score": 0.014,
      "adjusted_score": 0.014,
      "evidence_level": "weak",
      "trial_count": 0,
      "pub_count": 18,
      "recent_pubs": 4,
      "phases": [],
      "has_trials": false,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.8790406081849186,
      "model_score": 1.1774873434353137
    },
    {
      "drug": "Bevacizumab",
      "disease": "ulcerative colitis",
      "validation_score": 0.012,
      "adjusted_score": 0.012,
      "evidence_level": "weak",
      "trial_count": 0,
      "pub_count": 15,
      "recent_pubs": 4,
      "phases": [],
      "has_trials": false,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.8998280643198554,
      "model_score": 1.163660742453822
    },
    {
      "drug": "Panitumumab",
      "disease": "descending colon cancer",
      "validation_score": 0.006,
      "adjusted_score": 0.006,
      "evidence_level": "weak",
      "trial_count": 0,
      "pub_count": 7,
      "recent_pubs": 3,
      "phases": [],
      "has_trials": false,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.8677336631467557,
      "model_score": 1.1465323775923864
    },
    {
      "drug": "Trastuzumab",
      "disease": "multiple sclerosis",
      "validation_score": 0.004,
      "adjusted_score": 0.004,
      "evidence_level": "weak",
      "trial_count": 0,
      "pub_count": 5,
      "recent_pubs": 3,
      "phases": [],
      "has_trials": false,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.8893764240383933,
      "model_score": 1.098082878838592
    },
    {
      "drug": "Cetuximab",
      "disease": "descending colon cancer",
      "validation_score": 0.003,
      "adjusted_score": 0.003,
      "evidence_level": "weak",
      "trial_count": 0,
      "pub_count": 4,
      "recent_pubs": 1,
      "phases": [],
      "has_trials": false,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.88729386627701,
      "model_score": 1.1918426684043115
    },
    {
      "drug": "Ramucirumab",
      "disease": "descending colon cancer",
      "validation_score": 0.001,
      "adjusted_score": 0.001,
      "evidence_level": "weak",
      "trial_count": 0,
      "pub_count": 1,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": true,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.9181047595356134,
      "model_score": 1.1332343741472601
    },
    {
      "drug": "Cetuximab",
      "disease": "stomach carcinoma in situ",
      "validation_score": 0.0,
      "adjusted_score": 0.0,
      "evidence_level": "none",
      "trial_count": 0,
      "pub_count": 0,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": false,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.9234748452746652,
      "model_score": 1.155097089295893
    },
    {
      "drug": "Bevacizumab",
      "disease": "stomach carcinoma in situ",
      "validation_score": 0.0,
      "adjusted_score": 0.0,
      "evidence_level": "none",
      "trial_count": 0,
      "pub_count": 0,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": false,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.9147075182944621,
      "model_score": 1.1369317660583558
    },
    {
      "drug": "Panitumumab",
      "disease": "stomach carcinoma in situ",
      "validation_score": 0.0,
      "adjusted_score": 0.0,
      "evidence_level": "none",
      "trial_count": 0,
      "pub_count": 0,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": false,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.9266595175355842,
      "model_score": 1.1357391262412857
    },
    {
      "drug": "Pertuzumab",
      "disease": "descending colon cancer",
      "validation_score": 0.0,
      "adjusted_score": 0.0,
      "evidence_level": "none",
      "trial_count": 0,
      "pub_count": 0,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": false,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.881487299009659,
      "model_score": 1.1119127342583677
    },
    {
      "drug": "Ramucirumab",
      "disease": "stomach carcinoma in situ",
      "validation_score": 0.0,
      "adjusted_score": 0.0,
      "evidence_level": "none",
      "trial_count": 0,
      "pub_count": 0,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": false,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.9472244437541235,
      "model_score": 1.1061785027271283
    },
    {
      "drug": "Pertuzumab",
      "disease": "psoriasis",
      "validation_score": 0.0,
      "adjusted_score": 0.0,
      "evidence_level": "none",
      "trial_count": 0,
      "pub_count": 0,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": false,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.9259441650132709,
      "model_score": 1.1032898005997338
    },
    {
      "drug": "Pertuzumab",
      "disease": "ulcerative colitis",
      "validation_score": 0.0,
      "adjusted_score": 0.0,
      "evidence_level": "none",
      "trial_count": 0,
      "pub_count": 0,
      "recent_pubs": 0,
      "phases": [],
      "has_trials": false,
      "has_publications": false,
      "is_confounded": false,
      "confounding_type": null,
      "confounding_reason": null,
      "confounding_confidence": 0,
      "model_confidence": 0.9036462096145196,
      "model_score": 1.0986837031293555
    }
  ],
  "recommendation": "Remove weak oncology mAb predictions to improve precision. Future: add mechanism-based boosting for recall."
}